CA-BELKIN
2.2.2024 18:01:30 CET | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today announced a new division to the company, Future Ventures. This division will focus on opportunities and new avenues for Belkin to explore creative solutions for the modern world including content creation, spatial computing, Artificial Intelligence, robotics, and more. The first two products from this new line are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202187821/en/
The first two products from Belkin Future Ventures division are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro. (Photo: Business Wire)
Future Ventures will be comprised of forward-thinking designers, engineers and product managers all in-house at Belkin’s headquarters in El Segundo, CA and in satellite hubs worldwide. Belkin’s longstanding legacy in creating quality and human-centric peripheral mobile and computer accessories is the basis behind this new division, and steadily positions the company for new products and categories for the next generation.
“Belkin has been innovating for over 40 years, and Future Ventures was a clear next step in our plans to continue bringing new ideas to the table,” said Steve Malony, CEO, Belkin. “We know that good ideas come from anywhere, so we are looking everywhere to explore new categories and products that we believe in. Future Ventures opens the door to new markets that Belkin has not typically been part of in previous years. We experienced major success at CES 2024 with our new Auto-Tracking Stand Pro, but this is just the beginning of what this new division is capable of.”
The Auto-Tracking Stand Pro
The world’s first Apple certified Works with DockKit accessory, the Auto-Tracking Stand Pro provides seamless hands-free camerawork for content creators, filmmakers, educators, virtual presenters, social app developers, and more. DockKit’s automated subject tracking technology is designed to follow subjects on camera as they move around their space with 360 degrees of pan and 90 degrees of tilt. Additionally, the Auto-Tracking Stand Pro is made more responsibly with a minimum of 75% PCR materials and sold in plastic-free packaging in line with Belkin’s commitment to find more responsible ways to build products.
The Auto-Tracking Stand Pro is $179.99 USD and is available to pre-order on belkin.com. Media kit is available for download HERE.
Battery Holder for Apple Vision Pro
Designed to keep the Apple Vision Pro Battery secure, the Battery Holder allows for a convenient and versatile hands-free experience. The Battery Holder offers a quick and easy way to clip the battery onto a belt or pants, while the cross-body strap gives those without clip access a great way to secure the battery while using Apple Vision Pro.
The Battery Holder is $49.95 USD and is now available at apple.com. Media kit is available for download HERE.
For more information on Belkin’s products, please visit Belkin.com or follow Belkin on Instagram, Facebook, TikTok, LinkedIn and X.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202187821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom